
Hope for Britain's ash trees as study finds resistance evolving to killer fungus
British woodlands appear to be evolving resistance to the invasive fungus causing the devastating tree disease ash dieback, scientists have said.
Researchers from the Royal Botanic Gardens, Kew, and Queen Mary University of London say they have discovered a new generation of young ash trees in the wild which are showing greater resistance to the fungus compared to older trees.
The findings from the study focused on Marden Park wood in Surrey, a semi-natural ancient woodland dominated by ash, which is a species that produces a large number of seedlings from each adult.
It could mean ash does not go the same way as elms, which have been largely lost from the British landscape as a result of Dutch elm disease, the scientists said – although breeding programmes may be needed to bolster the fightback.
Ash dieback, which was first seen in the UK in 2012, causes leaf loss and crown dieback and can lead to tree death, with fears it could wipe out up to 85% of Britain's native ash trees, as they have not evolved natural defences against the fungus originally from Asia.
But now researchers suggest that natural selection in the wild is taking place on thousands of locations within ash tree DNA, driving increased resistance to the disease.
The study compared the DNA of ash trees established before and after the fungus arrived in Britain, and found shifts in variants associated with tree health in thousands of places across the overall genome of the trees.
This indicates the younger generation of trees has greater resistance to the fungus – as well as showing natural selection for a trait being influenced by multiple genes, which the researchers said was a phenomenon that was widely assumed but difficult to prove.
Their study in the journal Science said natural selection could be occurring partly due to reduced seed or pollen production by adult trees damaged by ash dieback, and partly through the rapid death of young trees infected by the fungus and so are not present in the wood.
But they cautioned that it was not yet known whether the rate of change would be enough to rescue the plants naturally, or whether there was enough genetic variation in ash trees to lead to a fully resistant tree.
The findings could be used to support breeding programmes that aim to make European ash trees resilient to the disease, they added.
Study author Dr Carey Metheringham, from Kew and Queen Mary, said: 'Thanks to natural selection, future generations of ash should have a better chance of withstanding infection.
'However, natural selection alone may not be enough to produce fully resistant trees.
'The existing genetic variation in the ash population may be too low, and as the trees become scarcer, the rate of selection could slow.
'Human intervention, such as selective breeding and the protection of young trees from deer grazing, may be required to accelerate evolutionary change.'
Another of the study's authors, Professor Richard Buggs, from Kew and Queen Mary, said: 'We are so glad that these findings suggest that ash will not go the way of the elm in Britain.
'Elm trees have struggled to evolve to Dutch elm disease, but ash are showing a very different dynamic because they produce an abundance of seedlings upon which natural selection can act when they are still young.
'Through the death of millions of ash trees, a more resistant population of ash is appearing.'
Rebecca Gosling, from the Woodland Trust which owns and manages Marden Park wood, said: 'Ash dieback demonstrates how devastating introduced pathogens can be for our trees and the species which rely upon them.
'This important research gives us hope for the future of our ash populations.'
She added: 'The findings highlight how vital it is to support natural regeneration in woodlands, furthering our understanding of how to best manage our ash woodlands.'
The study was mainly funded by the Environment Department (Defra) whose chief plant health officer Professor Nicola Spence said it demonstrated that tolerance to ash dieback can be inherited, and breeding programmes and natural regeneration together could secure the future of native ash.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
4 hours ago
- BBC News
New drug offers potential cure for ultra rare inherited condition
A teenager from Norfolk has become the first patient in Europe to be given a newly licensed treatment which could potentially cure her life-threatening, inherited Catchpole, 19, lost her mother, grandmother and several other relatives to the rare condition which affects the immune system, reducing her ability to fight infections."This treatment has brought me hope and joy," Mary told BBC News: "I feel like I can do anything, but it is bittersweet because my family members passed away before they could benefit."The newly licensed drug, leniolisib, is the first targeted treatment for her condition, Activated PI3-kinase Delta Syndrome or APDS. Not only is Mary the first patient to benefit from the drug but her family played a key role in research leading to the discovery of the ultra-rare was identified in 2013 by researchers at the University of Cambridge and clinicians at Addenbrooke's hospital who found a faulty gene carried by several members of Mary's Anita Chandra, consultant immunologist at Addenbrooke's Hospital and Affiliated Assistant Professor at the University of Cambridge said: "It is incredible to go from the discovery of a new disease in Cambridge to a treatment being approved and offered on the NHS, within the space of 12 years." Mary's father Jimmy said: "We just wanted to help, not just for our own sakes, but we'd heard there were other rare cases. "My wife volunteered for trials and, when Mary got old enough, she did too."Mary's mother Sarah died aged 43, her aunt aged 12, her uncle aged 39 and her grandmother at of Mary's cousins was successfully treated as a child with a bone marrow transplant, but these carry significant who was 12 when her mother died, told us: "It was always a fear that I would die young too but with this medication, I know I can have a longer life, which is what she wanted."In APDS, an enzyme produced in the body is "switched on" all the time, disrupting the development of white blood cells and causing the immune system to be with the condition are vulnerable to repeated lung infections which can lead to irreversible damage. It can cause organs and lymph nodes to swell, and the body's immune system to attack healthy tissue. Patients are also at risk of lymphoma, a cancer which affects a type of white blood drug, branded Joenja, is taken twice daily as tablets, and works by blocking the enzyme, allowing the immune system to work told the BBC: "This is something I have dreamt about since Mary was first diagnosed; it is giving her the chance to live a normal life."Mary suffered regular chest infections as a child and has been repeatedly treated with intravenous antibiotics, nebulisers and immunoglobulin replacement has been taking the leniolisib tablets for less than a month but has already stopped some other Chandra, who is Mary's consultant and has treated several other family members, said the drug was a "potential cure". Mary is rethinking about how she will live in future: "I want to go on more adventures and take risks because all I've ever known is medication, needles, and hospital appointments, whereas now I can find out who I truly am."The faulty gene is carried on the maternal line so there is a 50:50 chance it will be passed to affected women's children. Mary said she would like to become a dance teacher, while continuing her work as a teaching assistant. She said she had been cautious around people because of the risk of infection but no longer felt Sergey Nejentsev from the University of Cambridge who led the research that discovered APDS said: "As soon as we understood the cause of APDS, we immediately realised that certain drugs could be used to inhibit the enzyme that is activated in these patients. Leniolisib does precisely that. I am delighted that we finally have a treatment which will change the lives of APDS patients."Leniolisib has a list price of £352,000 a year, but was approved as cost effective by the health regulator NICE after the NHS negotiated a substantial, confidential estimates the drug could benefit up to 50 patients over the age of 12 in James Palmer, NHS England's Medical Director for Specialised Commissioning, said: "This treatment could be life-changing for those affected by this debilitating genetic disorder, and this important step forward is another example of the NHS's commitment to offering access to innovative medicines for those living with rare conditions."


Telegraph
6 hours ago
- Telegraph
Human genetic code to be built from scratch
The human genetic code will be built from scratch by British scientists in a controversial new research project. The £10 million scheme to synthesise DNA is being funded by the Wellcome Trust and involves scientists from universities including Oxford, Cambridge and Imperial College. Since the human genome was decoded at the start of the century, researchers have questioned whether it might be possible to use the blueprint to create genes and chromosomes artificially. In the five year project, the team hopes to create a fully synthetic human chromosome - making up about 2 per cent of human DNA - as a proof of concept. Michael Dunn, director of discovery research at Wellcome, said: ' Our DNA determines who we are and how our bodies work. 'Through creating the necessary tools and methods to synthesise a human genome we will answer questions about our health and disease that we cannot even anticipate yet, in turn transforming our understanding of life and wellbeing.' Researchers say synthetic genomes could help create new cell-based therapies or engineer plant species with new properties, such as being able to withstand pests and warming climates. Synthetic genomes have already been developed for small organisms such as the sexually transmitted bacterium Mycoplasma genitalium and But the human genome is much more complicated. However, experts said it is crucial to make sure the technology is not abused and that regulations are put in place. 'You can only truly understand something if you can build it from scratch,' said Prof Robin Lovell-Badge, group leader of the Francis Crick Institute in London. 'It is critical when developing new technology to understand not just issues of potential utility, but also those concerned with safety and risk. 'If these were to ever be used in humans, it would be important to design them carefully so that they can't lead to tumours or produce novel infectious particles. 'Indeed, I would urge incorporating an inducible genetic kill switch to eliminate them from any location in the body or at least to make them easy for the immune system to find and destroy.' The Wellcome Trust said it was commissioning a separate project to look into the ethics and public opinion on the research. Dr Pat Thomas, director of the campaign group Beyond GM, told the BBC: 'We like to think that all scientists are there to do good, but the science can be repurposed to do harm and for warfare'.


The Independent
7 hours ago
- The Independent
Controversial project could create human DNA from scratch
A controversial project that aims to create the building blocks of human life has started. It was previously thought creating human DNA could lead to designer babies or unforeseen complications and changes for future generations. However, in a world first, medical charity the Wellcome Trust, has given an initial £10m to start the project. Scientists say it has the potential to transform the understanding of human health, open opportunities to develop treatments for incurable diseases and develop climate-resistant crops. 'Our DNA determines who we are and how our bodies work,' said Michael Dunn, director of discovery research at Wellcome. 'Through creating the necessary tools and methods to synthesise a human genome, we will answer questions about our health and disease that we cannot even anticipate yet, in turn transforming our understanding of life and wellbeing.' In the next five to ten years scientists aim to build a full synthetic human chromosome. Every cell in the human body contains DNA, which is a molecule that carries genetic information that physically makes people who they are. The new Synthetic Human Genome Project will potentially allow researchers not just to be able to read DNA but create parts of it. Scientists will first aim to create larger blocks of human DNA to try to create a synthetically constructed a human chromosome – which contains genes that govern our development, repair and maintenance. These chromosomes would then be studied to find out how genes and DNA regulate our bodies. The project is led by Professor Jason Chin from the Generative Biology Institute at Ellison Institute of Technology and the University of Oxford, in collaboration with team of researchers from Cambridge, Kent, Manchester, Oxford and Imperial College London. 'The ability to synthesize large genomes, including genomes for human cells, may transform our understanding of genome biology and profoundly alter the horizons of biotechnology and medicine,' said Professor Chin. The project will be confined to test tubes and petri dishes, with no attempt to create synthetic life. But critics fear the research opens the way for researchers to create enhanced or modified humans. Professor Bill Earnshaw, a genetic scientist at Edinburgh University who designed a method for creating artificial human chromosomes fears this research could open the opportunity to attempt to create biological weapons, enhanced humans or even creatures that have human DNA. "The genie is out of the bottle," he told BBC News. "We could have a set of restrictions now, but if an organisation who has access to appropriate machinery decided to start synthesising anything, I don't think we could stop them." There will also be a dedicated social science project running alongside the researchers led by Professor Joy Zhang, a sociologist, at the University of Kent. "We want to get the views of experts, social scientists and especially the public about how they relate to the technology and how it can be beneficial to them and importantly what questions and concerns they have," she said.